Similarly, CDKN2B showed a significant decline in expression upon progressing to malignancy, with a mean expression of 2.566 in adenomas vs. 2.333 in adenocarcinomas (p = 0.002) (Figure 3B, left panel); these differences were even more pronounced in the paired comparison, where 65% of the adenomas exhibited higher CDKN2B expression compared to their matched cancerous tissue (p = 0.005) (Figure 3B, right panel). Here, CDKN2B is linked to adenocarcinoma.